Mayinglong Pharmaceutical Group Co Ltd Total Assets
Mayinglong Pharmaceutical Group Co Ltd total assets. Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) holds total assets worth CN¥5.64 Billion CNY (≈ $825.21 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Mayinglong Pharmaceutical Group Co Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
Total assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025. This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See Mayinglong Pharmaceutical Group Co Ltd share price for real-time trading data and today's change.
Mayinglong Pharmaceutical Group Co Ltd - Asset Composition Analysis
Mayinglong Pharmaceutical Group Co Ltd Total Assets Breakdown (December 2025)
Mayinglong Pharmaceutical Group Co Ltd total assets breakdown as of December 2025. Mayinglong Pharmaceutical Group Co Ltd's total assets of CN¥5.64 Billion consist of 70.0% current assets and 30.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 38.4% |
| Accounts Receivable | CN¥290.99 Million | 5.4% |
| Inventory | CN¥320.87 Million | 5.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥229.40 Million | 4.2% |
| Goodwill | CN¥22.99 Million | 0.4% |
Asset Composition Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Mayinglong Pharmaceutical Group Co Ltd (600993) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mayinglong Pharmaceutical Group Co Ltd's current assets represent 70.0% of total assets in 2025, an increase from 57.5% in 2001.
- Cash Position: Cash and equivalents constituted 38.4% of total assets in 2025, up from 31.1% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 5.9% of total assets.
Mayinglong Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Mayinglong Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Mayinglong Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.06 | 4.60 | 4.15 |
| Quick Ratio | 4.71 | 4.29 | 3.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.05 Billion | CN¥3.11 Billion | CN¥2.52 Billion |
Mayinglong Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Mayinglong Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | CN¥5.44 Billion |
| Market Capitalization | $1.58 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Mayinglong Pharmaceutical Group Co Ltd's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Mayinglong Pharmaceutical Group Co Ltd's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.44 Billion ≈ $795.49 Million |
+4.91% |
| 2024-12-31 | CN¥5.18 Billion ≈ $758.28 Million |
+7.30% |
| 2023-12-31 | CN¥4.83 Billion ≈ $706.71 Million |
-4.51% |
| 2022-12-31 | CN¥5.06 Billion ≈ $740.09 Million |
+22.55% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.90 Million |
+6.74% |
| 2020-12-31 | CN¥3.87 Billion ≈ $565.78 Million |
+17.68% |
| 2019-12-31 | CN¥3.29 Billion ≈ $480.76 Million |
+12.26% |
| 2018-12-31 | CN¥2.93 Billion ≈ $428.24 Million |
+6.27% |
| 2017-12-31 | CN¥2.75 Billion ≈ $402.99 Million |
+10.30% |
| 2016-12-31 | CN¥2.50 Billion ≈ $365.35 Million |
+3.60% |
| 2015-12-31 | CN¥2.41 Billion ≈ $352.64 Million |
+10.26% |
| 2014-12-31 | CN¥2.19 Billion ≈ $319.83 Million |
+7.80% |
| 2013-12-31 | CN¥2.03 Billion ≈ $296.68 Million |
+10.02% |
| 2012-12-31 | CN¥1.84 Billion ≈ $269.67 Million |
+11.18% |
| 2011-12-31 | CN¥1.66 Billion ≈ $242.56 Million |
+14.40% |
| 2010-12-31 | CN¥1.45 Billion ≈ $212.02 Million |
+0.91% |
| 2009-12-31 | CN¥1.44 Billion ≈ $210.11 Million |
+23.47% |
| 2008-12-31 | CN¥1.16 Billion ≈ $170.17 Million |
+6.53% |
| 2007-12-31 | CN¥1.09 Billion ≈ $159.74 Million |
-1.27% |
| 2006-12-31 | CN¥1.11 Billion ≈ $161.80 Million |
+43.23% |
| 2005-12-31 | CN¥772.00 Million ≈ $112.97 Million |
+13.04% |
| 2004-12-31 | CN¥682.94 Million ≈ $99.94 Million |
+85.61% |
| 2003-12-31 | CN¥367.95 Million ≈ $53.84 Million |
+1.33% |
| 2002-12-31 | CN¥363.13 Million ≈ $53.14 Million |
+13.16% |
| 2001-12-31 | CN¥320.89 Million ≈ $46.96 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more